Genmab A/S announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult ...

A yearlong battle between California’s Board of Pharmacy and firefighters intent on preserving their access to a treatment ...